Inactive

NON-COMPETITIVE COMBINED SYNOPSIS / SOLICITATION Title: Custom Synthesis of 1536 Antisense Oligonucleotides (ASOs) for CHCHD10 gene (i) This is a combined synopsis/solicitation for commercial items pr... NON-COMPETITIVE COMBINED SYNOPSIS / SOLICITATION Title: Custom Synthesis of 1536 Antisense Oligonucleotides (ASOs) for CHCHD10 gene (i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii) The solicitation number is 75N95022Q00252 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures; and FAR Part 12—Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold. THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institute on Drug Abuse (NIDA), NIDA Office of Acquisitions on behalf of the National Center for Advancing Translational Sciences (NCATS) Section, intends to negotiate and award a purchase order without providing for full and open competition (Including brand-name) to Integrated DNA Technologies, Inc., 1710 Commercial Park, Coralville, IA, 52241-2760, for Custom Synthesis of Antisense Oligonucleotides (ASOs). The anticipated award date is 6/29/2022. This acquisition is non-competitive due to the need for scientific continuity. The required oligonucleotides have previously been used to perform research. To ensure continuity of science, we must continue to use these exact oligonucleotides since to introduce any other vendor's items, made using different processes and procedures, could compromise data integrity and invalidate results. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2022-06, dated 05/01/2022. (iv) The associated NAICS code 325414 and the small business size standard is 1250 employees. This requirement has no set-aside restrictions. (v) Project requirements: Synthesize and deliver quantity 1,536 antisense oligonucleotides targeting the CHCHD10 (Entrez gene id 400916) human gene. The antisense oligonucleotides will be customized according to sequences specified by NCATS. The antisense oligonucleotides will be synthesized, purified using standard desalting methods, and normalized to the required quantity and concentration. The oligos will be plated in 384-well Deep Well plates and hydrated to 100uM in 100uL of ID TE pH 8.0 buffer. Oligos must be shipped via overnight delivery on dry ice. Shipping costs must be included in quote. (vi) Delivery Location: The National Center for Advancing Translational Sciences (NCATS) 9800 Medical Center Drive Rockville, MD 20850 (vii) The provision at FAR clause 52.212-1, Instructions to Offerors – Commercial Products and Commercial Services, applies to this acquisition. (viii) The provision at FAR clause 52.212-2, Evaluation – Commercial Products and Commercial Services, applies to this acquisition. (a) The award resulting from this solicitation will be made to the responsible offeror whose proposal is most advantageous to the Government, Technical Capability, Past Performance, and other factors considered. (ix) Offerors are to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications—Commercial Products and Commercial Services, with its offer. (x) The FAR clause at 52.212-4, Contract Terms and Conditions – Commercial Products and Commercial Services, applies to this acquisition. The following FAR provisions or clauses are incorporated by reference: 52.204-7, System for Award Management (Oct 2018) 52.204-13, System for Award Management Maintenance (Oct 2018) 52.204-16, Commercial and Entity Code Reporting (Aug 2020) 52.204-18, Commercial and Entity Code Maintenance (Aug 2020) 52.204-24, Representation Regarding Certain Telecommunications and Video Surveillance Services of Equipment (include date) HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (December 18, 2015). 52.212-4(g), Invoice, is supplemented by the NIH Invoice and Payment Instructions (2/2014). (xi) FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders–Commercial Products and Commercial Services, applies to this acquisition (xii) HHS reserves the right to exercise priorities and allocations authority with respect to this contract, to include rating this order in accordance with 45 CFR Part 101, Subpart A - Health Resources Priorities and Allocations System. (xiii) The offeror must complete and return FAR 52.204-24 with its offer. (xiv) Responses to this solicitation must include sufficient information to establish the interested parties’ bona-fide capabilities of providing the product or service. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered in the award decision. Such factors may include: past performance; special features required for effective program performance; trade-in considerations; probable life of the item selected as compared with that of a comparable item; warranty considerations; maintenance availability; and environmental and energy efficiency considerations. In addition the Unique Entity Identifier (UEI), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.” All responses must be received by June 1, 2022, 9:00 am, Eastern Standard Time and reference number 75N95022Q00252. Responses shall be submitted electronically to Samson Shifaraw, Contracts Specialist, samson.shifaraw@nih.gov. Fax responses will not be accepted. (xv) The name of the individual to contact for information regarding the solicitation: Samson Shifaraw, Contracts Specialist, samson.shifaraw@nih.gov. Attachments: FAR 52.212-5 Copy of FAR 52.204-24, to be completed and submitted by offeror Invoice and payment provisions